Drug intelligence / Profile preview

ORA102

Development stage: Phase 2
Lead developer: Ora Bio
Modality: Small Molecules
Administration: Intravitreal

Overview

ORA102 is an investigational drug developed by Ora Bio Ltd. It is being evaluated in a Phase I/II pilot study for the treatment of neovascular Age-related Macular Degeneration (AMD) when combined with Avastin (Bevacizumab). The drug is administered via intravitreal injections.

Other names: acitretin

Targets

RARA (Retinoic acid receptor alpha)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)

Beyond the preview

Go deeper on ORA102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORA102.

Explore the full profile